IP Library › Granted Patent US 10,676,507
Granted Patent B2
US 10,676,507 · App. 15/576,111 · Granted Jun 9, 2020

Peptide and composition containing the same for anti-inflammation, anti-fibrosis, wound healing, and anticancer treatment

Inventor: Sang Jae Kim (Seoul, KR)
Assignee: GEMVAX & KAEL CO., LTD.
C07K7/06A61P1/00A61P1/04A61P1/16A61P3/10A61P11/00A61P17/00A61P17/02A61P17/06A61P19/00A61P19/02A61P25/00A61P29/00A61P35/00A61P37/00A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,676,507
App. No.
15/576,111
Granted
Jun 9, 2020
Kind
B2
Abstract

Peptides and compositions comprising the peptides, and more particularly, a peptide effective in anti-inflammation, anti-fibrosis, wound healing, and anti-cancer treatment, and a composition including the same are described. The peptides provided herein and the compositions comprising the peptides exhibit an effect of alleviating, preventing, or treating inflammation, fibrosis, wounds, and symptoms of diseases such as cancer including these symptoms, and thus may provide a method of preventing or treating associated diseases.

Claims (18)

1. A peptide having an amino acid sequence of SEQ ID NO:12 or consisting of an amino acid sequence of SEQ ID NO:10.

2. A pharmaceutical composition comprising the peptide or a pharmaceutically acceptable salt thereof according to claim 1 .

3. The pharmaceutical composition of claim 2 , wherein the composition has an anti-inflammatory activity due to a decrease in TNF-α.

4. The pharmaceutical composition of claim 3 , wherein the composition prevents or treats any one or more inflammation-associated diseases selected from the group consisting of rheumatoid arthritis, psoriasis, psoriatic arthritis, atopic dermatitis, inflammatory bowel diseases, ulcerative colitis, Crohn's disease, ankylosing spondylitis, multiple sclerosis, systemic lupus erythematosus (SLE), chronic obstructive pulmonary disease (COPD), septicemia, endotoxin shock, hepatitis, and type 1 diabetes.

5. The pharmaceutical composition of claim 2 , wherein the composition alleviates fibrosis of a body organ.

6. The pharmaceutical composition of claim 5 , wherein the composition has an activity of inhibiting fibrosis of a body organ by TGF-β signaling inhibition.

7. The pharmaceutical composition of claim 5 , wherein the composition prevents or treats fibrosis induced by one or more selected from the group consisting of cancer, administration of an anticancer drug, and radiation exposure.

8. The pharmaceutical composition of claim 7 , wherein the cancer is selected from the group consisting of pancreatic cancer, colon cancer, stomach cancer, prostate cancer, non-small cell lung cancer, breast cancer, melanoma, and ovarian cancer.

9. The pharmaceutical composition of claim 2 , wherein the composition treats or alleviates a wound.

10. The pharmaceutical composition of claim 9 , wherein the composition has a wound healing effect by inducing collagen synthesis.

11. The pharmaceutical composition of claim 9 , wherein the wound is selected from the group consisting of epidermal burns, epidermal lacerations, epidermal wounds, and combinations thereof.

12. The pharmaceutical composition of claim 2 , wherein the composition improves a skin condition.

13. The pharmaceutical composition of claim 12 , wherein the skin condition is selected from the group consisting of skin wrinkles according to skin aging, skin dryness, scars, reduced skin elasticity, and skin dents.

14. The pharmaceutical composition of claim 2 , wherein the composition is an anti-cancer composition.

15. A pharmaceutical kit comprising:

the pharmaceutical composition according to claim 2 ; and

an instruction instructing one or more selected from a dose, administration route, the number of doses, and indications of the composition.

16. A cosmetic composition comprising the peptide or a salt thereof according to claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2023
From: GEMVAX & KAEL CO. LTD.
To: GEMVAX & KAEL CO. LTD.; KIM, SANG JAE
Reel/Frame 065471/0754 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: KIM, SANG JAE
To: GEMVAX & KAEL CO., LTD.
Reel/Frame 044390/0339 →
Priority Claims (1)
KR 10-2015-0073188 · May 26, 2015 · national
Continuity (1)
Related Publication 20180134749A1 · May 17, 2018